Moderna Cancer Trial Success Is a Shot in the Arm for Trump
Summary
Moderna and Merck announced success in a late-stage trial of a personalized mRNA cancer vaccine for melanoma, which led to a significant rise in Moderna's stock price. The treatment uses mRNA to help the immune system target cancer cells based on each patient’s unique tumor, a scientific advance developed during President Trump's first term but tested more recently under President Biden.Key Facts
- Moderna and Merck tested a personalized mRNA cancer vaccine in a Phase 3 trial for melanoma patients.
- The vaccine trains the immune system to recognize and attack cancer cells specific to each patient.
- The trial involved 1,137 patients with surgically removed stage IIB-IV melanoma.
- Results showed significant improvements in patient survival rates.
- Moderna’s stock nearly doubled in premarket trading after the announcement.
- The vaccine development began in 2017 during President Trump’s first term but its late-stage trial started under President Biden.
- President Trump highlighted mRNA and AI’s role in future cancer treatments during his 2025 return to office.
- In 2025, Health and Human Services planned to end mRNA vaccine funding for respiratory diseases, moving toward other vaccine types.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
